Tenon Medical, Inc. reported its financial results for the third quarter ended September 30, 2024, on November 13, 2024. The company posted revenue of $0.9 million for the quarter, which was a 1.6% decrease compared to the second quarter of 2024.
Despite the quarterly dip, year-to-date revenue reached $2.5 million, marking an 18.3% increase compared to the prior year period. The company also highlighted the publication of an interim analysis from its MAINSAIL™ study, which supports the safety and efficacy of the Catamaran SI Joint Fusion System.
Further strategic advancements included the successful completion of initial clinical procedures with the new Catamaran SE platform and the granting of three U.S. patents. Additionally, Tenon Medical received net proceeds of approximately $9.6 million from equity financing transactions, strengthening its financial position.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.